Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis

OBJECTIVE: To explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective. METHODS: A Markov model, adapted from the one established in Finland was conducted for the cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Jianzhou, Li, Caiyun, Zhang, Xuefang, Cheng, Luyan, Ding, Ruilin, Zhang, Lingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339785/
https://www.ncbi.nlm.nih.gov/pubmed/35923949
http://dx.doi.org/10.3389/fpubh.2022.942800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339785/
https://www.ncbi.nlm.nih.gov/pubmed/35923949
http://dx.doi.org/10.3389/fpubh.2022.942800

Ejemplares similares